Quality in general practice
Quality is a fashionable concept in health care, but what it means or how to measure it is not always clear; when National Health Service (NHS) trusts were set up in the early 1 990s they seemed to see quality assurance as a branch of marketing, which, as one health authority GP advisor put it, 'assures us that the quality is excellent'. Fortunately, this fashion for advertising rhetoric (often at variance with reality) seems to have passed.
More positively, quality is taken to mean ensuring that agreed standards are met by measuring the process and outcome of care. In this sense quality is closely related to audit, and is sometimes no more than 'accounting by counting'. This works best for clearly defined issues where the objectives are not in doubt; therefore attention to quality of care has usually focused on problems where groups require a standard package of treatment for which there is a clear evidence base. The desirable outcome is often uncontroversial, and so quality is a matter of determining the best means to an agreed end, rather than the more complex evaluation of what ends are most important. It is therefore unsurprising that quality measures have usually addressed process rather than outcome and the biomechanical rather than the holistic; hypertension and diabetes surveillance, rather than bereavement and the quality of the doctor-patient relationship. As Practice, have demonstrated the feasibility of developing robust measures of the interpretative function of medicine. Their paper is part of a large study looking at various aspects of care in six Scottish fundholding practices, involving 49 doctors, over 5000 patients and almost nine thousand consultations. In an attempt to assess quality in the general practice consultation they have devised a measure of 'enablement'. This is based on the response to six questions designed to elicit patient's feelings of confidence, ability and coping after a consultation. They found that enablement scores correlated highly with consultation length.
Their work is by no means unproblematic. The philosophical justification for valuing enablement rather than outcomes is not clear. Like many health service managers, they seem to be in pursuit of the Holy Grail of one simple index of quality. Health care is complex, and attempts to reduce it to one dimension are doomed to failure. Correlation does not imply causation, and whether enablement is the result of the longer consultations, or whether both have a common cause only contingently related to consultation length, has not been established. Howie et al. point out that their instrument needs to be compared with other measures such as patient satisfaction indices and the use of routinely available NHS data as performance indicators, and tested in other types of practice and social settings. They have done careful psychometric work on construct validity and reliability of the instrument, but present no evidence of external validation of their measure. No matter how carefully constructed it may be, a questionnaire that does not predict behaviour is of limited value. Do patients who say they feel more enabled actually cope better with their illnesses? Does the extra investment in consultation time pay off in lower drug use, fewer referrals, earlier return to work or activity and less long-term disability, or do longer consultations merely provide greater opportunities to plumb the depths of human misery? Is it simply quantity of time that matters, or does the nature of what goes on during that time make a difference?
Despite these weaknesses, the study has two major lessons for health care planning. The first is that, with careful research and even more careful thought, the interpretative function of medicine and its human face can be measured. Bruster et al.3 reached similar conclusions about hospital care, from a study that unpacked the superficial notion of patient satisfaction. There is no longer any excuse for nihilism about measurement in this area, nor for restricting the study of quality to biomechanical aspects of medical care.
Perhaps more importantly, the thesis that Howie et al. propose-that enablement depends on having sufficient time in the consultation presents a serious challenge to health service planning. To increase consultation length by 20%, which their work implies is desirable, would require either 20% more medical time or some major changes in the way consultations are organized. Medical time is expensive. To increase the number of general practitioners (GPs) by 20% would cost almost £300m in salaries alone.
This may be value for money in economic as well as human terms if enablement leads to lower costs elsewhere in the NHS or to better social functioning. Too often, aspects of health care spending are examined in isolation from the larger picture. We need to measure the social as well as the human cost of illness.
Money is not the only limiting factor. There is an overall shortage of doctors, and particularly a recruitment crisis to general practice. More and more doctors wish to work part-time for all or part of their career. Community-based undergraduate medical education and GP commissioning may be admirable, but both take GPs away from spending time with their patients. Since it takes three years from entering vocational training and ten from entering medical school to produce a general practitioner, the medical workforce cannot be augmented rapidly.
It may not be medical time that is required. Some say that what we need is a change in skill mix, with greater use of nurses and nurse practitioners. This would, however, change the nature of general practice. Patients might have to choose which problems to present to the doctor and which to the nurse or nurse practitioner. Continuity of care and the patient-clinician relationship would be affected. These changes should be piloted and evaluated before being widely adopted. Too many innovations have been made in primary care on the basis of belief rather than evidence, with thought only on what will be gained and not on what might be lost. This is true of the move from single-handed to group practice and multidisciplinary teams as well as of anticipatory care, fundholding and GP commissioning. Before making further changes we need a clearer vision of what we seek to achieve as well as better evidence on how to achieve it.
Are you a commander or a guide?
Analysing some 150 published accounts of personal illness, Anne Hunsaker Hawkins identifies two important metaphors that help people come to terms with their experiences1. The first is the battle, in which disease is the enemy to be defeated with the aid of doctors, nurses, and medical weaponry. The second is the journey, whereby the sick person ventures into unknown territory, undergoes frightening ordeals, and emerges with new vision and insight. According to Hawkins, these are 'enabling myths', with roots in Western culture going back to the Iliad (warfare) and the Odyssey (quest). For the battle the patient needs a general, for the journey a guide and interpreter.
In long-term illness especially, the journey myth seems to be gaining ground, and several themes in the JRSM come together here. For example, in January we had Christina Funnell's article on partnership in medical care, discussing the benefit people gain from having some control over the impact of their illnesses; in February there was JM Leggett's critique of 'therapeutic totalitarianism' (still being debated in the correspondence columns); and in this issue we have Peter Toon's editorial about the relation between consultation time and patient 'enablement' and Susanne Ax's analysis of discord between patients and doctors on the matter of chronic fatigue syndrome. To these I add Rampes' plea for inclusion of complementary medicine in the medical curriculum (January), on a hunch that 'alternative' practitioners succeed less by their special techniques than by offering moral support on the health journey; without this enormous prop, could a health service ever cope?
Christina Funnell invited me to a meeting in Paris entitled Partners in the Health Care Journey attended by patients' representatives and a scattering of doctors, nurses, and people from the pharmaceutical industry (which helped to fund it through a group called Pharmaceutical Partners for Better Healthcare)2. Here are a few things I wrote down:
How strange that in 1997 we should be discussing whether patients should participate in decisions about their care. Listen to the patients; we have information on what it's like to take drugs. Partnership is based on communication, but we don't speak the same language. We ought to examine the human dimensions of outstanding clinicians.
